Skip to main content

Advertisement

SpringerLink
Log in

Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma

  • Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

This study aimed to examine the prognostic relevance of glucose transporter type 1 (GLUT-1), which is a key regulator of the glucose metabolism. In particular, the study aimed to examine the association between GLUT-1 expression and the therapeutic effect of chemoradiotherapy (CRT) in pancreatic ductal adenocarcinoma (PDAC).

Methods

Patients with PDAC were enrolled in the study. Patients with distant metastases and those who received only chemotherapy as treatment were excluded from the study. Specimens for immunohistochemical evaluations were obtained through surgical resection and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of the primary tumor before any treatment.

Results

This study included 197 patients. Of these 197 patients, 100 underwent upfront surgery, and 97 received neoadjuvant CRT (NACRT), which was performed mainly for patients with locally advanced tumors. Of the 97 patients who received NACRT, 21 later underwent surgical resection. For the patients who underwent upfront surgery, low GLUT-1 expression was an independent factor for a better prognosis. For the patients who underwent NACRT, low GLUT-1 expression was significantly associated with greater tumor size reduction, a higher resection rate, and a better prognosis. Additionally, GLUT-1 expression was significantly increased after NACRT treatment.

Conclusions

Among the patients with PDAC, those with low GLUT-1 expression in the primary tumor had a better prognosis those with high GLUT-1 expression. Moreover, the patients with low GLUT-1 expression displayed a better therapeutic response to NACRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol. 2012;18:736–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  4. Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008; 26:942–47.

    Article  CAS  PubMed  Google Scholar 

  5. Shinchi H, Maemura K, Mataki Y, et al. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci. 2012;19:152–58.

    Article  PubMed  Google Scholar 

  6. Takahashi H, Akita H, Tomokuni A, et al. Preoperative gemcitabine-based chemoradiation therapy for borderline resectable pancreatic cancer: impact of venous and arterial involvement status on surgical outcome and pattern of recurrence. Ann Surg. 2016;264:1091–97.

    Article  PubMed  Google Scholar 

  7. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330:1340–44.

    Article  CAS  PubMed  Google Scholar 

  8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  PubMed  Google Scholar 

  9. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.

    Article  CAS  PubMed  Google Scholar 

  10. Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012;18:5585–94.

    Article  CAS  PubMed  Google Scholar 

  11. Luo XM, Xu B, Zhou ML, Bao YY, Zhou SH, Fan J, Lu ZJ. Co-inhibition of GLUT-1 expression and the PI3K/Akt signaling pathway to enhance the radiosensitivity of laryngeal carcinoma xenografts in vivo. PloS One. 2015;10:e0143306.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654–62.

    Article  CAS  PubMed  Google Scholar 

  13. Zhang C, Liu J, Liang Y, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun. 2013;4:2935.

    PubMed  PubMed Central  Google Scholar 

  14. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol. 2004;381:335–54.

    Article  CAS  PubMed  Google Scholar 

  15. Shin SH, Kim SC, Hong SM, Kim YH, Song KB, Park KM, Lee YJ. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas. 2013;42:216–22.

    Article  CAS  PubMed  Google Scholar 

  16. Kim H, Saka B, Knight S, et al. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res, 2014;20:1865–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995;15:2895–8.

    CAS  PubMed  Google Scholar 

  18. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34–40.

    Article  CAS  PubMed  Google Scholar 

  19. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634–41.

    Article  CAS  PubMed  Google Scholar 

  20. Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin down-regulates the hypoxia response genes: HIF-1alpha, GLUT-1, and VEGF in human pancreatic cancer cells. J Surg Res. 2011;167:173–81.

    Article  CAS  PubMed  Google Scholar 

  21. Basturk O, Singh R, Kaygusuz E, Kaygusuz E, Balci S, Dursun N, Adsay NV. GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas. 2011;40:187–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sharen G, Peng Y, Cheng H, Liu Y, Shi Y, Zhao J. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget. 2017;8:19760–7.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer (2010) TNM Classification of Malignant Tumours. 7th ed.Wiley-Blackwell, Chichester.

    Google Scholar 

  24. Maemura K, Shinchi H, Noma H, et al. Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer. Anticancer Res. 2008;28:2369–72.

    PubMed  Google Scholar 

  25. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  26. Chikamoto A, Inoue R, Komohara Y, et al. Preoperative high maximum standardized uptake value in association with glucose transporter 1 predicts poor prognosis in pancreatic cancer. Ann Surg Concol. 2017;24:2040–6.

    Article  Google Scholar 

  27. Erickson RA. EUS-guided FNA. Gastrointest Endosc. 2004;60:267–79.

    Article  PubMed  Google Scholar 

  28. Higashi M, Yokoyama S, Yamamoto T, et al. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma. Pancreas. 2015;44:728–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kurahara H, Maemura K, Mataki Y, Sakoda M, Shinchi H, Natsugoe S. Impact of p53 and PDGFR-beta expression on metastasis and prognosis of patients with pancreatic cancer. World J Surg. 2016;40:1977–84.

    Article  PubMed  Google Scholar 

  30. Yamada R, Mizuno S, Uchida K, et al. Human equilibrative nucleoside transporter 1 expression in endoscopic ultrasonography-guided fine-needle aspiration biopsy samples is a strong predictor of clinical response and survival in the patients with pancreatic ductal adenocarcinoma undergoing gemcitabine-based chemoradiotherapy. Pancreas. 2016;45:761–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgment

This study was funded by Grants-in-Aid for Scientific Research (26462067) from the Japan Society for the Promotion of Science, Ministry of Health, Labour and Welfare, Japan.

Disclosure

There are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan

    Hiroshi Kurahara MD, PhD, Kosei Maemura MD, PhD, Yuko Mataki MD, PhD, Masahiko Sakoda MD, PhD, Satoshi Iino MD, PhD, Yota Kawasaki MD, PhD, Takaaki Arigami MD, PhD, Shinichiro Mori MD, PhD, Yuko Kijima MD, PhD & Shoji Natsugoe MD, PhD

  2. Department of Clinical Oncology, Kagoshima University, Kagoshima, Japan

    Shinichi Ueno MD, PhD

  3. Department of Health Sciences, Kagoshima University, Kagoshima, Japan

    Hiroyuki Shinchi MD, PhD

Authors
  1. Hiroshi Kurahara MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kosei Maemura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuko Mataki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiko Sakoda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoshi Iino MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yota Kawasaki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takaaki Arigami MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shinichiro Mori MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuko Kijima MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shinichi Ueno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hiroyuki Shinchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shoji Natsugoe MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Kurahara MD, PhD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 15 kb)

Supplementary material 2 (DOCX 16 kb)

Supplementary material 3 (DOCX 14 kb)

Supplementary material 4 (DOCX 16 kb)

10434_2018_6357_MOESM5_ESM.jpg

Fig. S1 Kaplan–Meier survival curves from the initial treatment (surgery) for patients who underwent upfront surgery.. Supplementary material 5 (JPEG 690 kb)

10434_2018_6357_MOESM6_ESM.jpg

Fig. S2 Kaplan–Meier survival curves from the initial treatment for patients who underwent neoadjuvant chemoradiotherapy (NACRT). a Overall survival (OS) of patients who underwent surgical resection after NACRT. b Recurrence-free survival of patients who underwent surgical resection after NACRT. c OS of patients who did not undergo surgical resection after NACRT. d Progression-free survival of patients who did not undergo surgical resection after NACRT. Supplementary material 6 (JPEG 1027 kb)

10434_2018_6357_MOESM7_ESM.jpg

Fig. S3 Kaplan–Meier survival curves from the initial treatment for patients who underwent neoadjuvant chemoradiotherapy (NACRT). Eight patients experienced a low-to-high change in glucose transporter type 1 (GLUT-1) expression due to NACRT. Supplementary material 7 (JPEG 712 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kurahara, H., Maemura, K., Mataki, Y. et al. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 25, 1432–1439 (2018). https://doi.org/10.1245/s10434-018-6357-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6357-1

Keywords

Search

Navigation